The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

Transition Bio and Voyager have teamed to discover and develop new small molecules that target toxic TDP-43 protein clumps in ...

A brain-computer interface capable of decoding Mandarin Chinese from brain signals may help people with paralysis or ALS to ...

The ALS prevalence is expected to rise across multiple nations by 2040 due to aging populations and increased ALS survival ...

Preclinical data showed imaging agent ACI-19626 can selectively bind to abnormal clumps of the TDP-43 protein, a hallmark of ...

Columnist Juliet Taylor discusses the Tim Lowrey ALS Panel Series, which has provided tailored information to 1,500 people ...

Teaming up with the Healey & AMG Center, Inflammasome will advance its oral ALS drug kamuvudine-9, known as K9, into early clinical testing.

These days, columnist Dagmar Munn is all about manipulating the algorithm of her brain to improve her outlook and turn down ...

Researchers in Germany say combining two blood biomarkers may make the diagnosis of ALS more accurate and help predict ...

Oprah's interview with Emma Heming Willis resonated with columnist Kristin Neva, who reflects on life as an ALS caregiver.

SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.